Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 213-720-7 | CAS number: 1004-38-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- May - July 1980
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 980
- Report date:
- 1980
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Version / remarks:
- Equivalent to Version dated May 1981
- Deviations:
- yes
- Remarks:
- - Acclimatization period was minimum 4 days, instead of at least 5 days as recommended by guideline - Volume should not exceed 10 ml/kg (OECD), in the study 12.5 ml/kg were used as max - No constant volume was used (concentrations were not adjusted)
- Principles of method if other than guideline:
- The study was performed prior to the implementation of the OECD test guideline 401 in May 1981. However, procedures are very similar to the later enforced guideline and was thus concluded to be equivalent to the test guideline with acceptable restrictions.
- GLP compliance:
- no
- Remarks:
- pre-GLP
- Limit test:
- no
Test material
- Reference substance name:
- Pyrimidine-2,4,6-triyltriamine
- EC Number:
- 213-720-7
- EC Name:
- Pyrimidine-2,4,6-triyltriamine
- Cas Number:
- 1004-38-2
- Molecular formula:
- C4H7N5
- IUPAC Name:
- 2,4,6-Triaminopyrimidine
- Test material form:
- solid
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source: Lonza AG
- Purity: 98.7%
- Melting point: 254-256.5°C
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: room temperature
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Final dilution of a dissolved solid: 40% w/v
FORM AS APPLIED IN THE TEST: suspension
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River UK Limited, Margate, Kent, England
- Females nulliparous and non-pregnant: yes (virgin)
- Age at study initiation: approx. 7 weeks
- Weight at study initiation: 170-180 g
- Fasting period before study: Approx. 18 +/- 2 hours prior to and 4 hours after dosing
- Housing: groups
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: minimum 4 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 23 +/- 2
- Humidity (%): 47 (median)
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: To:
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 40% w/v suspension
- Amount of vehicle (if gavage): depending on dose. (max volume applied 12.5 ml/kg)
MAXIMUM DOSE VOLUME APPLIED: 12.5 ml/kg
DOSAGE PREPARATION: The test sample was prepared freshly on the day of dosing
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: - Doses:
- 1000, 2500, and 5000 mg/kg bw applied as 40% w/v suspension
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- PRELIMIARY STUDY:
- establishing a dosing regimen
- two males and two females per dose level
- dosage levels: 1000, 2500, and 5000 mg/kg bw
- Duration of observation period following administration: 15 or 21 days
MAIN STUDY:
- Concentration of test substance in the vehicle was the same for all dosage levels
- Dosed volume was varied to achieve necessary dosage level
- Duration of observation period following administration: 15 days
- Frequency of observations and weighing: Observed soon after dosing, then hourly on day 1. Subsequnetly, animals were observed once in the morning and once at the end of the experimental day. Clinical signs were observed at each observation.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight - Statistics:
- Acute oral median LD50 was calculated using the method of Finney (1971) Probit Analysis (3rd Edition) Cambridge University Press.
Results and discussion
- Preliminary study:
- Results of the preliminary study indicated that the LD50 was in the region of 2500 to 5000 mg/kg bw.
Effect levelsopen allclose all
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 2 050 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- > 733 - < 3 241
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 2 500 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: could not be calculated from the mortality pattern, but appeared to be in the region of 2500 mg/kg bw.
- Mortality:
- Death occurred amongst rats at 1000 mg/kg bw and above from within one and ten days of dosing (see table 1). At 3200 mg/kg bw, one male was killed in extremis on Day 7. Autopsy revealed amongst these animals congestion and hemorrhages in the lungs and pallor of the liver, spleen and kidneys.
- Clinical signs:
- other: In all treated rats, pilo-erection and abnormal body carriage (hunched posture) shortly after dosing was observed. Recovery of the survivors as judged by external appearance and behavior was apparently complete within 14 days of dosing with the exception
- Gross pathology:
- At 1000, 3200, and 5000 mg/kg bw, a brown or white creamy coloration of the gastric contents amongst rats. Gaseous distension of the stomach and a red coloration of the peritoneum in one male and one female, respectively, at 5000 mg/kg bw. Dark coloration of the liver in one female at 1000 mg/kg bw and enlarged, pale adrenals in two females at 3200 mg/Kg bw. A swollen gelatinous preputial gland and undersized seminal vesicles, small spleen with granular surface, congestion of the peritoneal blood vessel and hemorrhages in the lunggs in the male at 3200 mg/kg bw that was killed in extremis. Terminal autopsy findings were within normal limits.
Any other information on results incl. tables
Table 1: Mortality data for groups of rats - preliminary study
Dosage (mg/kg bw) |
Mortality ratio |
Time of death after dosing (days) |
||
Male |
Female |
Combined |
||
1000 |
0/2 |
0/2 |
0/4 |
- |
2500 |
1/2 |
1/2 |
2/4 |
<2 - <3 |
5000 |
1/2 |
1/2 |
2/4 |
<1 - <3 |
Table 2: Mortality ratio and group mean body weight (g) of rats - main study
Sex |
Dosage (mg/kg bw) |
Body weight (g) at |
Mortality ratio |
Time of death after dosing (days) |
||
Dosing |
1 week |
2 weeks |
||||
Male |
1000 |
188 |
260 |
304 |
0/5 |
- |
2500 |
187 |
251 |
299 |
2/5 |
<4 |
|
3200 |
192 |
148+ |
DIED |
5/5 |
<2 – 6 |
|
5000 |
174 |
DIED |
- |
5/5 |
<2 – 3 |
|
Female |
1000 |
168 |
202 |
221 |
1/5 |
<1 |
2500 |
175 |
153 |
220 |
2/5 |
<4 |
|
3200 |
168 |
118+ |
159 |
4/5 |
<2 - <4 |
|
5000 |
166 |
115+ |
DIED |
5/5 |
<1 - <10 |
+ = One rat only
Table 3: Signs of reaction to treatment ratio of rats - main study
Signs |
Signs of reaction ratio |
|||
Dose (mg/kg bw) |
||||
1000 |
2500 |
3200 |
5000 |
|
Pilo-erection |
10/10 |
10/10 |
10/10 |
10/10 |
Abnormal body carriage (hunched posture) |
10/10 |
10/10 |
10/10 |
10/10 |
Abnormal gait (waddling) |
3/10 |
10/10 |
10/10 |
10/10 |
Lethargy |
1/10 |
10/10 |
10/10 |
10/10 |
Decreased respiratory rate |
0/10 |
2/10 |
10/10 |
10/10 |
Increased lacrimation (discolored red) |
0/10 |
1/10 |
5/10 |
5/10 |
Ptosis |
0/10 |
3/10 |
2/10 |
3/10 |
Abnormal gait (walking on toes) |
0/10 |
3/10 |
2/10 |
1/10 |
Diarrhoea |
0/10 |
3/10 |
0/10 |
1/10 |
Diuresis |
0/10 |
2/10 |
0/10 |
1/10 |
Pallor of the extremities |
0/10 |
0/10 |
5/10 |
3/10 |
Fine body tremors |
0/10 |
0/10 |
3/10 |
3/10 |
Coarse body tremors |
0/10 |
0/10 |
0/10 |
1/10 |
Ataxia |
0/10 |
0/10 |
0/10 |
1/10 |
Gasping respiration |
0/10 |
0/10 |
0/10 |
1/10 |
Increased salivation |
0/10 |
0/10 |
0/10 |
1/10 |
Penis swollen and enlarged |
0/10 |
0/10 |
1/10 |
0/10 |
Applicant's summary and conclusion
- Interpretation of results:
- Category 5 based on GHS criteria
- Conclusions:
- The acute median lethal oral dose (LD50) and its 95% confidence limits to rats of the test substance were calculated to be 2050 (733 to 3241) mg/kg bw, 2156 (1486 to 2735) mg/kg bw, and 2500 mg/kg bw for females only, males and females combined, and males only in the region of this value, respectively.
- Executive summary:
An acute oral toxicity test was performed in order to investigate the toxic potential of the test substance. Ten (five male and five female) Wistar rats were dosed to 1000, 2500, 3200, and 5000 mg/kg bw of the test substance. The concentration of the test substance was 40% w/v in corn oil. Body weight was meaured at dosing and then weekly thereafter. At 2500 mg/kg bw, two out of five males died. At 3200 mg/kg bw and above, all males (5/5) died. At 1000 mg/kg bw, one out of five females died. Two out of five, four out of five, and all females died at 2500, 3200, and 5000 mg/kg, respectively. Clinical signs, auch as abnormal gait (waddling) and lethargy were observed at 1000 mg/kg bw (females only) and above (males and females). Other clinical signs included decreased respiratory rate, fine body tremors, ataxia, and diarrhoea, among others. The LD50 for males and females was 2500 mg/kg bw and 2050 mg/kg bw, respectively. LD50 were calculated according to mortality patterns, however, for females only because male LD50 could not be calculated from mortality patterns.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.